Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response
- PMID: 21490770
- PMCID: PMC3065911
- DOI: 10.1155/2011/274629
Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response
Abstract
High-density lipoprotein (HDL) is a major carrier of cholesterol in the blood. Unlike other lipoproteins, physiological functions of HDL influence the cardiovascular system in favorable ways except when HDL is modified pathologically. The cardioprotective mechanism of HDL is mainly based on reverse cholesterol transport, but there has been an emerging interest in the anti-inflammatory and antioxidant roles of HDL. These latter activities of HDL are compromised in many pathological states associated with inflammation. Further, abnormal HDL can become proinflammatory contributing to oxidative damage. In this paper, we discuss the functional heterogeneity of HDL, how alterations in these particles in inflammatory states result in loss of both antioxidant activity and reverse cholesterol transport in relation to atherosclerosis, and the need for assays to predict its functionality.
Figures


Similar articles
-
High-density lipoprotein: antioxidant and anti-inflammatory properties.Curr Atheroscler Rep. 2007 Sep;9(3):244-8. doi: 10.1007/s11883-007-0026-3. Curr Atheroscler Rep. 2007. PMID: 18241620 Review.
-
HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity.Biomedicines. 2021 Jun 25;9(7):729. doi: 10.3390/biomedicines9070729. Biomedicines. 2021. PMID: 34202201 Free PMC article. Review.
-
Lipid disorders and their relevance to outcomes in chronic kidney disease.Blood Purif. 2011;31(1-3):189-96. doi: 10.1159/000321845. Epub 2011 Jan 10. Blood Purif. 2011. PMID: 21228589 Review.
-
Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.Biochimie. 2014 Jan;96:56-66. doi: 10.1016/j.biochi.2013.08.027. Epub 2013 Sep 5. Biochimie. 2014. PMID: 24012775 Review.
-
Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010. J Ren Nutr. 2010. PMID: 20797569 Review.
Cited by
-
Quantitative Serum NMR Spectroscopy Stratifies COVID-19 Patients and Sheds Light on Interfaces of Host Metabolism and the Immune Response with Cytokines and Clinical Parameters.Metabolites. 2022 Dec 16;12(12):1277. doi: 10.3390/metabo12121277. Metabolites. 2022. PMID: 36557315 Free PMC article.
-
Lipid and brain volumetric measures in multiple sclerosis patients: findings from a large observational study.Acta Neurol Belg. 2024 Dec;124(6):1981-1988. doi: 10.1007/s13760-024-02676-w. Epub 2024 Oct 25. Acta Neurol Belg. 2024. PMID: 39455532 Free PMC article.
-
TNF Inhibitors Exert a "Hidden" Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients.Biologics. 2022 Oct 17;16:187-197. doi: 10.2147/BTT.S364191. eCollection 2022. Biologics. 2022. PMID: 36281333 Free PMC article.
-
High Density Lipoprotein and it's Dysfunction.Open Biochem J. 2012;6:78-93. doi: 10.2174/1874091X01206010078. Epub 2012 Jul 27. Open Biochem J. 2012. PMID: 22888373 Free PMC article.
-
Association between Perchlorate and Indirect Indicators of Thyroid Dysfunction in NHANES 2001-2002, a Cross-Sectional, Hypothesis-Generating Study.Biomark Insights. 2011;6:135-46. doi: 10.4137/BMI.S7985. Epub 2011 Dec 1. Biomark Insights. 2011. PMID: 22174568 Free PMC article.
References
-
- Gordon DJ, Rifkind BM. High-density lipoprotein–the clinical implications of recent studies. New England Journal of Medicine. 1989;321(19):1311–1316. - PubMed
-
- Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham heart study. Arteriosclerosis. 1988;8(6):737–741. - PubMed
-
- Barter P, Kastelein J, Nunn A, et al. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003;168(2):195–211. - PubMed
-
- Asztalos BF, Schaefer EJ. HDL in atherosclerosis: actor or bystander? Atherosclerosis. 2003;4(1):21–29. - PubMed
-
- Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews. 2006;58(3):342–374. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources